| 36.25 Real-Time Quote |  -0.53 / -1.44%Today’s Change | 17.06 Today|||52-Week Range 42.41 | +62.99% Year-to-Date |
| Elan Provides Strategic Update - Analyst Blog May 21 / Zacks.com | Elan in Royalty Deal with THRX - Analyst Blog May 14 / Zacks.com |
| Elan steps up fight against Royalty Pharma bid May 20 / FT.com | Glaxo/THRX's Breo Ellipta Gets FDA Nod - Analyst Blog May 13 / Zacks.com |
| Previous close | 36.78 |
| Today’s open | 36.32 |
| Day’s range | 36.25 - 36.60 |
| Volume | 170,539 |
| Average volume (3 months) | 1,553,736 |
| Market cap | $3.7B |
| Dividend yield | -- |
| Earnings growth (last year) | +85.82% |
| Earnings growth (this year) | -887.00% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +453.84% |
| P/E ratio | NM |
| Price/Sales | 14.89 |
| Price/Book | 23.34 |
| Today’s change | Today’s % change | |
|---|---|---|
| SLXPSalix Pharmaceutical... | +0.13 | +0.22% |
| JAZZJazz Pharmaceuticals... | +0.05 | +0.08% |
| MDVNMedivation Inc | -1.33 | -2.67% |
| ENDPEndo Health Solution... | -0.49 | -1.43% |
| Next reporting date | July 25, 2013 |
| EPS forecast (this quarter) | -$0.53 |
| Annual revenue (last year) | $135.8M |
| Annual profit (last year) | -$18.5M |
| Net profit margin | -13.66% |
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer Rick E. Winningham, MBA |
CFO, Senior VP & Head-Investor Relations Michael W. Aguiar, MBA |
Corporate headquarters South San Francisco, California |
.
